Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 13

1.

Importance of immunoglobulin heavy chain variable region mutational status in del(13q) chronic lymphocytic leukemia.

Gladstone DE, Swinnen L, Kasamon Y, Blackford A, Gocke CD, Griffin CA, Meade JB, Jones RJ.

Leuk Lymphoma. 2011 Oct;52(10):1873-81. doi: 10.3109/10428194.2011.585529. Epub 2011 Aug 18.

2.

Chronic lymphocytic leukemia in a Japanese population: varied immunophenotypic profile, distinctive usage of frequently mutated IGH gene, and indolent clinical behavior.

Tomomatsu J, Isobe Y, Oshimi K, Tabe Y, Ishii K, Noguchi M, Hirano T, Komatsu N, Sugimoto K.

Leuk Lymphoma. 2010 Dec;51(12):2230-9. doi: 10.3109/10428194.2010.527403. Epub 2010 Nov 11.

PMID:
21067444
3.

Allogeneic stem cell transplantation provides durable disease control in poor-risk chronic lymphocytic leukemia: long-term clinical and MRD results of the German CLL Study Group CLL3X trial.

Dreger P, Döhner H, Ritgen M, Böttcher S, Busch R, Dietrich S, Bunjes D, Cohen S, Schubert J, Hegenbart U, Beelen D, Zeis M, Stadler M, Hasenkamp J, Uharek L, Scheid C, Humpe A, Zenz T, Winkler D, Hallek M, Kneba M, Schmitz N, Stilgenbauer S; German CLL Study Group.

Blood. 2010 Oct 7;116(14):2438-47. doi: 10.1182/blood-2010-03-275420. Epub 2010 Jul 1.

4.

ZAP-70, IgVh, and cytogenetics for assessing prognosis in chronic lymphocytic leukemia.

Trojani A, Montillo M, Nichelatti M, Tedeschi A, Colombo C, Veronese S, Mura MA, Ricci F, Scarpati B, Colosimo A, Lodola M, Morra E.

Cancer Biomark. 2010;6(1):1-9. doi: 10.3233/CBM-2009-0114.

PMID:
20164537
5.

De novo deletion 17p13.1 chronic lymphocytic leukemia shows significant clinical heterogeneity: the M. D. Anderson and Mayo Clinic experience.

Tam CS, Shanafelt TD, Wierda WG, Abruzzo LV, Van Dyke DL, O'Brien S, Ferrajoli A, Lerner SA, Lynn A, Kay NE, Keating MJ.

Blood. 2009 Jul 30;114(5):957-64. doi: 10.1182/blood-2009-03-210591. Epub 2009 May 4.

6.

A subset of Binet stage A CLL patients with TP53 abnormalities and mutated IGHV genes have stable disease.

Best OG, Gardiner AC, Davis ZA, Tracy I, Ibbotson RE, Majid A, Dyer MJ, Oscier DG.

Leukemia. 2009 Jan;23(1):212-4. doi: 10.1038/leu.2008.260. Epub 2008 Sep 25. No abstract available.

PMID:
18818700
7.

Allogeneic hematopoietic stem-cell transplantation for chronic lymphocytic leukemia with 17p deletion: a retrospective European Group for Blood and Marrow Transplantation analysis.

Schetelig J, van Biezen A, Brand R, Caballero D, Martino R, Itala M, García-Marco JA, Volin L, Schmitz N, Schwerdtfeger R, Ganser A, Onida F, Mohr B, Stilgenbauer S, Bornhäuser M, de Witte T, Dreger P.

J Clin Oncol. 2008 Nov 1;26(31):5094-100. doi: 10.1200/JCO.2008.16.2982. Epub 2008 Aug 18.

PMID:
18711173
8.

Clinical and therapeutic implications of the mutational status of IgVH in patients with chronic lymphocytic leukemia.

Kharfan-Dabaja MA, Chavez JC, Khorfan KA, Pinilla-Ibarz J.

Cancer. 2008 Sep 1;113(5):897-906. doi: 10.1002/cncr.23671. Review.

9.

Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial.

Catovsky D, Richards S, Matutes E, Oscier D, Dyer MJ, Bezares RF, Pettitt AR, Hamblin T, Milligan DW, Child JA, Hamilton MS, Dearden CE, Smith AG, Bosanquet AG, Davis Z, Brito-Babapulle V, Else M, Wade R, Hillmen P; UK National Cancer Research Institute (NCRI) Haematological Oncology Clinical Studies Group; NCRI Chronic Lymphocytic Leukaemia Working Group.

Lancet. 2007 Jul 21;370(9583):230-9.

PMID:
17658394
10.
11.

Genomic aberrations and survival in chronic lymphocytic leukemia.

Döhner H, Stilgenbauer S, Benner A, Leupolt E, Kröber A, Bullinger L, Döhner K, Bentz M, Lichter P.

N Engl J Med. 2000 Dec 28;343(26):1910-6.

12.

Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia.

Hamblin TJ, Davis Z, Gardiner A, Oscier DG, Stevenson FK.

Blood. 1999 Sep 15;94(6):1848-54.

13.

Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia.

Damle RN, Wasil T, Fais F, Ghiotto F, Valetto A, Allen SL, Buchbinder A, Budman D, Dittmar K, Kolitz J, Lichtman SM, Schulman P, Vinciguerra VP, Rai KR, Ferrarini M, Chiorazzi N.

Blood. 1999 Sep 15;94(6):1840-7.

Supplemental Content

Support Center